FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2469701130> ?p ?o ?g. }

• W2469701130 endingPage "1151" @default.
• W2469701130 startingPage "1147" @default.
• W2469701130 abstract "OBJECTIVE To study the feasibility of adenoviral transduction of Herceptin complete antibody gene and its effect on Her2 over-expressing cancer. METHODS The genes of VH and VL from the monoclonal antibody Herceptin were cloned into the genome of replication-defective adenovirus by viral recombination technology to produce the recombinant adenovirus Ad-SG-Her. Normal human liver cells of the line L-02 were transfected with Ad-SG-Her and ELISA was used to detect the expression of Herceptin antibody 3 and 7 days after. Forty BALB/c nude mice were inoculated with Her2 high-expressing oophoroma cells of SK-OV-3 line and were randomized into 4 equal groups: group A injected with Ad-SG-Her at the dosage of: 2 x 10(9) plaque forming unit (pfu) through the caudal vein, group B injected with Ad-SG-Her at the dosage of 1 x 10(9) pfu, group C injected with Ad-SG-Her at the dosage of 5 x 10(8) pfu, and control group. On the days 3, 7, 10, 14, 21, 28, and 35 after the injection of virus, the antibody expression in the serum was measured by ELISA and the size of tumor was measured vernier caliper. Western blot and IFA was used to detect the specificity for Her2-overexpressing ovarian cancer cell lines SK-OV-3 and the integrity of complete antibody. Anti-tumor effects were also observed in nude mice bearing SK-OV-3 tumors. RESULTS The constructed recombinant adenovirus Ad-SG-Her could express Herceptin efficiently both in vitro and in vivo. The biological activity of the expressed antibody was similar to that of the commercial Herceptin as shown by Western blotting, IFA, and ELISA. Herceptin expression of Ad-SG-Her was detected since day 3 after treatment in the groups A, B, and C and reached the peak on days 7 - 10. The expression lasted for four weeks or so. The expression level was significantly different between group A and the groups B and C (all P < 0.05), however, without a significant difference between the group B and group C. The antibody expression of group A might increase to 103.5 micro g/ml, high enough to inhibit tumor growth and induce tumor cell apoptosis. The antibody expression of the group B was below 40 micro g/ml, and that of the group C was below 30 micro g/ml. Furthermore the expressed antibody doses were statistically significantly different at different time points. Almost no tumor growth was seen in the group A during the observation period in comparison with the groups B and C and the control group (all P < 0.05). The tumor growth was almost not influenced in the group B and C and the control group. CONCLUSION Ad-SG-Her efficiently expresses humanized complete Herceptin with effective bioactivity and induces long-term stable expression both in vitro and in vivo. The system may serve as a new antitumoral gene therapy strategy in antibody field." @default.
• W2469701130 created "2016-07-22" @default.
• W2469701130 creator A5042680484 @default.
• W2469701130 creator A5044642052 @default.
• W2469701130 creator A5044871527 @default.
• W2469701130 creator A5045409917 @default.
• W2469701130 creator A5064454778 @default.
• W2469701130 creator A5070838435 @default.
• W2469701130 creator A5080096095 @default.
• W2469701130 creator A5090394529 @default.
• W2469701130 date "2004-07-17" @default.
• W2469701130 modified "2023-09-24" @default.
• W2469701130 title "[Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene]." @default.
• W2469701130 doi "https://doi.org/10.3760/j:issn:0376-2491.2004.14.002" @default.
• W2469701130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15387973" @default.
• W2469701130 hasPublicationYear "2004" @default.
• W2469701130 type Work @default.
• W2469701130 sameAs 2469701130 @default.
• W2469701130 citedByCount "1" @default.
• W2469701130 crossrefType "journal-article" @default.
• W2469701130 hasAuthorship W2469701130A5042680484 @default.
• W2469701130 hasAuthorship W2469701130A5044642052 @default.
• W2469701130 hasAuthorship W2469701130A5044871527 @default.
• W2469701130 hasAuthorship W2469701130A5045409917 @default.
• W2469701130 hasAuthorship W2469701130A5064454778 @default.
• W2469701130 hasAuthorship W2469701130A5070838435 @default.
• W2469701130 hasAuthorship W2469701130A5080096095 @default.
• W2469701130 hasAuthorship W2469701130A5090394529 @default.
• W2469701130 hasConcept C104317684 @default.
• W2469701130 hasConcept C111599444 @default.
• W2469701130 hasConcept C153911025 @default.
• W2469701130 hasConcept C159047783 @default.
• W2469701130 hasConcept C159654299 @default.
• W2469701130 hasConcept C203014093 @default.
• W2469701130 hasConcept C32470452 @default.
• W2469701130 hasConcept C40767141 @default.
• W2469701130 hasConcept C54009773 @default.
• W2469701130 hasConcept C542903549 @default.
• W2469701130 hasConcept C54355233 @default.
• W2469701130 hasConcept C55493867 @default.
• W2469701130 hasConcept C81885089 @default.
• W2469701130 hasConcept C86803240 @default.
• W2469701130 hasConceptScore W2469701130C104317684 @default.
• W2469701130 hasConceptScore W2469701130C111599444 @default.
• W2469701130 hasConceptScore W2469701130C153911025 @default.
• W2469701130 hasConceptScore W2469701130C159047783 @default.
• W2469701130 hasConceptScore W2469701130C159654299 @default.
• W2469701130 hasConceptScore W2469701130C203014093 @default.
• W2469701130 hasConceptScore W2469701130C32470452 @default.
• W2469701130 hasConceptScore W2469701130C40767141 @default.
• W2469701130 hasConceptScore W2469701130C54009773 @default.
• W2469701130 hasConceptScore W2469701130C542903549 @default.
• W2469701130 hasConceptScore W2469701130C54355233 @default.
• W2469701130 hasConceptScore W2469701130C55493867 @default.
• W2469701130 hasConceptScore W2469701130C81885089 @default.
• W2469701130 hasConceptScore W2469701130C86803240 @default.
• W2469701130 hasIssue "14" @default.
• W2469701130 hasLocation W24697011301 @default.
• W2469701130 hasLocation W24697011302 @default.
• W2469701130 hasOpenAccess W2469701130 @default.
• W2469701130 hasPrimaryLocation W24697011301 @default.
• W2469701130 hasRelatedWork W2058438178 @default.
• W2469701130 hasRelatedWork W2154150796 @default.
• W2469701130 hasRelatedWork W2349027243 @default.
• W2469701130 hasRelatedWork W2349290146 @default.
• W2469701130 hasRelatedWork W2350062997 @default.
• W2469701130 hasRelatedWork W2352763860 @default.
• W2469701130 hasRelatedWork W2354086060 @default.
• W2469701130 hasRelatedWork W2366770558 @default.
• W2469701130 hasRelatedWork W2371436664 @default.
• W2469701130 hasRelatedWork W2374941916 @default.
• W2469701130 hasRelatedWork W2381650363 @default.
• W2469701130 hasRelatedWork W2381881651 @default.
• W2469701130 hasRelatedWork W2432995475 @default.
• W2469701130 hasRelatedWork W2774640062 @default.
• W2469701130 hasRelatedWork W2939509174 @default.
• W2469701130 hasRelatedWork W2982606454 @default.
• W2469701130 hasRelatedWork W2990765768 @default.
• W2469701130 hasRelatedWork W3029436396 @default.
• W2469701130 hasRelatedWork W3029619791 @default.
• W2469701130 hasRelatedWork W3150255988 @default.
• W2469701130 hasVolume "84" @default.
• W2469701130 isParatext "false" @default.
• W2469701130 isRetracted "false" @default.
• W2469701130 magId "2469701130" @default.
• W2469701130 workType "article" @default.